Here's Why Moderna's Growth May Be Just Getting Started

·4 min read
Here's Why Moderna's Growth May Be Just Getting Started

Moderna (NASDAQ: MRNA) stock might look a bit expensive these days. At the same time, some investors wonder whether Moderna may have reached peak sales of its coronavirus vaccine. Right now, it's too early to predict if and when coronavirus vaccine sales will slow.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting